Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | CDC25B | P30305 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046961 | 0.84 | MALT1 (0.45) | MEN1KMT2AMAOAMAOBALDH1A1 | |
| SCHEMBL20046950 | 0.80 | MALT1 (0.44) | MEN1KMT2AMAOAMAOBALDH1A1 | |
| SCHEMBL20046758 | 0.76 | MAOA (0.50) | MEN1KMT2AMAOAMAOBALDH1A1 | |
| Anthraquinone SCHEMBL15309434 | 0.76 | KMT2A (0.54) | MEN1KMT2APABPC1MAOAALDH1A1 | |
| SCHEMBL20046959 | 0.75 | HKDC1 (0.50) | MEN1KMT2AMAOAMAOBALDH1A1 | |
| SCHEMBL28055855 | 0.73 | CYP1A2 (0.59) | MEN1KMT2APABPC1MAOAALDH1A1 | |
| SCHEMBL30231841 | 0.72 | ALDH1A1 (0.54) | MEN1KMT2APABPC1MAOAALDH1A1 | |
| SCHEMBL15859643 | 0.72 | MEN1 (0.72) | MEN1KMT2APABPC1MAOAALDH1A1 | |
| SCHEMBL15859646 | 0.69 | MEN1 (0.64) | MEN1KMT2APABPC1MAOAALDH1A1 | |
| SCHEMBL31171425 | 0.68 | MEN1 (0.55) | MEN1KMT2AMAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| WO-2018067842-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | MEN1 1754/4885KMT2A 498/4885PABPC1 3377/4885 |
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | MCL1, NPM1, ABL1 | MEN1 1754/4885KMT2A 498/4885PABPC1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.